Oncology Biosimilar Roundup for January 2021
Findings from biosimilar studies of Kanjinti (trastuzumab) and Mvasi and Zirabev (bevacizumab) rounded out our oncology biosimilar coverage in January.
Study: Bevacizumab Biosimilar Finds Acceptance in First-Line Treatment of mCRC
Investigators noted comparable use of bevacizumab biosimilar and reference products among patients treated for metastatic colorectal cancer (mCRC).
Investigators Study Risks of Hypertension, Proteinuria With Bevacizumab
The study was designed to elucidate incidence of hypertension and proteinuria in patients treated with bevacizumab reference vs biosimilar products.
Swift Uptake for Mvasi Suggests Provider Comfort With Use
Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.
